Dados B3 › GRND3 × AMER3
GRND3 × AMER3
Indicators
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | GRND3 | AMER3 | year |
|---|---|---|---|
| ROE | 17.9% | -5.6% | 2025 |
| ROIC | 12.0% | 3.4% | 2025 |
| ROA | 14.3% | -1.6% | 2025 |
| Gross margin | 45.2% | 27.0% | 2025 |
| EBIT margin | 12.6% | 2.7% | 2025 |
| Net margin | 25.0% | -2.2% | 2025 |
| Net debt/EBITDA | -2.32x | 0.83x | 2025 |
| Current ratio | 2.05x | 1.67x | 2025 |
| Revenue growth (1y) | -1.7% | -1.2% | 2025 |
| Revenue growth (5y CAGR) | 6.4% | 4.0% | 2025 |
| Piotroski F-Score | 4/9 | 3/9 | 2025 |
Point-in-time multiples
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | GRND3 | AMER3 | year |
|---|---|---|---|
| P/E | 6.87x | -3.81x | 2025 |
| P/B | 1.40x | 0.22x | 2025 |
| EV/EBITDA | 8.10x | 1.73x | 2025 |
| FCF yield | 9.5% | 34.5% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-09 14:51 UTC. If this does not match /saude, you are reading a cached copy.
Sources: CVM (open data, ODbL) and B3 (COTAHIST). Not affiliated with B3 or the CVM. Not investment advice.